If it was determined that APO E4 interacted epistatically with one other gene, which form of epistasis would result in more people being stricken with the disorder, dominant epistasis or recessive epistasis? Select an answer and submit. For keyboard navigation, use the up/down arrow keys to select an answer. a) Recessive epistasis, since it would result in as many as 6.25% of people developing the disorder. b)Recessive epistasis, since it would result in as many as 75% of people developing the disorder. c) Dominant epistasis, since it would result in as many as 56% of people developing the disorder. d) Dominant epistasis, since it would result in as many as 75% of people developing the disorder. 2) Suppose researchers find out that APO E4 and APO E2 have a codominant relationship. What is the likelihood a heterozygous patient would have of developing Alzheimer’s in a worst-case scenario? Select an answer and submit. For keyboard navigation, use the up/down arrow keys to select an answer. a) 50%! b) 100%! c) 25%! d) 75%!
Alzheimer’s is a progressive neurological disorder resulting in dementia and memory loss that occurs in 10% of the US population older than 65. In the 1990s, several researchers showed evidence that the allele of a cholesterol precursor gene, APO E4, increased risk of developing the disorder compared to APO E2 or APO E3. This was especially pronounced if patients carried two alleles of APO E4. However, not all people with APO E4 develop the disorder and some without it will present with Alzheimer's nevertheless. This suggests other genes influence development of the disease. Current research has elucidated dozens of genes that interact with APO E4 pathways in hundreds of ways. As many as 27 of the interactions are epistatic, with some as dominant epistasis and some as recessive epistasis. In addition, some of the gene candidates for non-APO E4 Alzheimer’s have other relationships such as dominant, codominant or incomplete dominant. No reliable cure currently exists for Alzheimer’s although some treatments may slow progression of the disease. A recent medication that was rushed through approval for Alzheimer's, aducanumab, was released last year, but whether or not is has any effect is doubtful in trials that have been completed so far.
1)
Step by step
Solved in 3 steps
